BUTLER HOSPITAL
- Type
- Teaching hospital
- Where
- PROVIDENCE, RI
- Medicare CCN
- 414000
- Received
- $3,910,715 in 91 records, 2019 ($52,973 general, $3,857,742 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Butler Hospital Fuzzy (name and state)
- Federal award recipient: BUTLER HOSPITAL Fuzzy (name and state)
- Nonprofit: BUTLER HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 4 | $52,973 |
| 2019 | Research payment | 87 | $3,857,742 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Biogen, Inc. | 3 | $2,090,638 | 2019 |
| Eli Lilly and Company | 7 | $1,163,232 | 2019 |
| Genentech, Inc. | 53 | $453,591 | 2019 |
| Eisai Inc. | 4 | $99,456 | 2019 |
| GenMark Diagnostics, Inc. | 2 | $49,624 | 2019 |
| Janssen Research & Development, LLC | 14 | $34,919 | 2019 |
| Merck Sharp & Dohme LLC | 6 | $15,905 | 2019 |
| Digital Cognition Technologies, Inc. | 1 | $3,240 | 2019 |
| Merge Healthcare Incorporated | 1 | $108 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 87 | $3,857,742 |
| Honoraria | 1 | $49,590 |
| Gift | 1 | $3,240 |
| Food and Beverage | 2 | $142 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-23 | Janssen Research & Development, LLC | $1,286 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-12-21 | Eisai Inc. | $68,856 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2019 |
| 2019-12-17 | Genentech, Inc. | $20,117 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-12-12 | Genentech, Inc. | $18,490 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-12-05 | Genentech, Inc. | $14,999 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-12-05 | Genentech, Inc. | $4,450 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-11-25 | Janssen Research & Development, LLC | $1,573 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-11-21 | Eisai Inc. | $16,190 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2019 |
| 2019-11-15 | Genentech, Inc. | $10,448 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-11-15 | Genentech, Inc. | $2,128 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-11-14 | Genentech, Inc. | $2,402 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-11-01 | Genentech, Inc. | $18,134 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-11-01 | Genentech, Inc. | $432 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-28 | Janssen Research & Development, LLC | $2,173 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-10-24 | Genentech, Inc. | $22,074 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-21 | GenMark Diagnostics, Inc. | $34 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-10-17 | Janssen Research & Development, LLC | $3,986 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-10-08 | Eisai Inc. | $7,509 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2019 |
| 2019-10-04 | Genentech, Inc. | $8,900 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-04 | Genentech, Inc. | $432 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-04 | Genentech, Inc. | $108 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $33,963 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $8,900 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $4,340 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $432 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $108 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Genentech, Inc. | $108 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-09-27 | Janssen Research & Development, LLC | $1,623 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-09-23 | Eisai Inc. | $6,900 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2019 |
| 2019-09-03 | Genentech, Inc. | $5,762 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-08-23 | Genentech, Inc. | $4,533 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-08-19 | Genentech, Inc. | $18,041 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-07-29 | Janssen Research & Development, LLC | $1,948 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-07-19 | Genentech, Inc. | $11,230 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-07-17 | Genentech, Inc. | $17,654 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-07-16 | Eli Lilly and Company | $343,275 | Research payment | Cash or cash equivalent | ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | 2019 | |
| 2019-07-01 | Genentech, Inc. | $17,545 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-07-01 | Genentech, Inc. | $10,550 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-06-28 | Janssen Research & Development, LLC | $1,598 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-06-06 | Merge Healthcare Incorporated | $108 | Food and Beverage (5 payments) | Cash or cash equivalent | Device, Medical Imaging | 2019 | |
| 2019-06-03 | Genentech, Inc. | $2,402 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-05-27 | Janssen Research & Development, LLC | $2,960 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-05-16 | Genentech, Inc. | $20,441 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-04-25 | Janssen Research & Development, LLC | $1,623 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-04-23 | Genentech, Inc. | $17,121 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-04-09 | Digital Cognition Technologies, Inc. | $3,240 | Gift (3 payments) | In-kind items and services | Device, Cognition | 2019 | |
| 2019-04-01 | Genentech, Inc. | $8,900 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-04-01 | Genentech, Inc. | $432 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-04-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-04-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-25 | Janssen Research & Development, LLC | $1,598 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-03-18 | Genentech, Inc. | $7,458 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-11 | Genentech, Inc. | $8,900 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-11 | Genentech, Inc. | $4,450 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $24,447 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $13,350 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $10,396 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $8,900 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $519 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $216 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-03-01 | Genentech, Inc. | $98 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-02-27 | Merck Sharp & Dohme LLC | $2,098 | Research payment | Cash or cash equivalent | MK-8931 Drug, NEUROSCIENCE | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safet | 2019 |
| 2019-02-25 | Janssen Research & Development, LLC | $1,948 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-02-19 | Genentech, Inc. | $20,248 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-02-19 | Genentech, Inc. | $3,595 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-02-12 | Genentech, Inc. | $3,758 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GTP1 PHASE I LONGITUDINAL STUDY | 2019 |
| 2019-02-06 | Genentech, Inc. | $21,772 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-02-05 | Eli Lilly and Company | $650,500 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2019 | |
| 2019-02-04 | Genentech, Inc. | $346 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-02-01 | Janssen Research & Development, LLC | $8,648 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-01-31 | Eli Lilly and Company | $2,300 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2019 | |
| 2019-01-31 | Eli Lilly and Company | $1,080 | Research payment | In-kind items and services | ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | 2019 | |
| 2019-01-28 | Janssen Research & Development, LLC | $2,422 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-01-18 | Janssen Research & Development, LLC | $1,533 | Research payment | Cash or cash equivalent | A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy | 2019 | |
| 2019-01-15 | Merck Sharp & Dohme LLC | $6,772 | Research payment | Cash or cash equivalent | MK-8931 Drug, NEUROSCIENCE | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safet | 2019 |
| 2019-01-15 | Merck Sharp & Dohme LLC | $2,623 | Research payment | Cash or cash equivalent | MK-8931 Drug, NEUROSCIENCE | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safet | 2019 |
| 2019-01-15 | Eli Lilly and Company | $900 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI | 2019 | |
| 2019-01-03 | Eli Lilly and Company | $53,009 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | 2019 | |
| 2019-01-03 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | MK-8931 Drug, NEUROSCIENCE | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safet | 2019 |
| 2019-01-03 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | MK-8931 Drug, NEUROSCIENCE | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safet | 2019 |
| 2019-01-03 | Merck Sharp & Dohme LLC | $411 | Research payment | Cash or cash equivalent | MK-8931 Drug, NEUROSCIENCE | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safet | 2019 |
| 2019-01-02 | Biogen, Inc. | $775,920 | Research payment | Cash or cash equivalent | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | 2019 | |
| 2019-01-02 | Biogen, Inc. | $259,723 | Research payment | Cash or cash equivalent | Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A IgG1 mAb) in Participants With Prodromal or | 2019 | |
| 2019-01-02 | Eli Lilly and Company | $112,168 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI | 2019 | |
| 2019-01-02 | Genentech, Inc. | $18,257 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-01-01 | Biogen, Inc. | $1,054,993 | Research payment | Cash or cash equivalent | 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | 2019 | |
| 2019-01-01 | GenMark Diagnostics, Inc. | $49,590 | Honoraria | In-kind items and services | ePlex Device, multiplex molecular testing system | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Providence, RI, county Providence County, RI, state Rhode Island; placed by its city name.
| Measure | Place (city or town) Providence, RI | County Providence County, RI | State Rhode Island |
|---|---|---|---|
| Population B01003 | 191,767 | 664,854 | 1,101,801 |
| Population, 2020 census P1 | 190,934 | 660,741 | 1,097,379 |
| Median age B01002 | 32.8 | 38.0 | 40.6 |
| Under 18 B01001 | 20.1% | 20.1% | 18.8% |
| 65 and over B01001 | 11.6% | 16.3% | 18.7% |
| Households B11001 | 71,497 | 259,210 | 441,570 |
| Foreign born B05002 | 33.5% | 20.9% | 15.3% |
| Median household income B19013 | $68,119 | $78,787 | $87,796 |
| Median family income B19113 | $80,994 | $99,120 | $112,375 |
| Per capita income B19301 | $37,138 | $41,523 | $47,150 |
| Poverty rate B17001 | 20.7% | 13.4% | 11.2% |
| Unemployment rate B23025 | 8.2% | 6.6% | 5.8% |
| Civilian labor force B23025 | 101,717 | 358,122 | 594,253 |
| Mean commute (minutes) B08013 | 25.0 | 25.9 | 25.5 |
| Bachelor's degree or higher B15003 | 34.6% | 32.3% | 37.7% |
| Housing units B25001 | 79,423 | 277,740 | 485,932 |
| Owner-occupied B25003 | 41.4% | 56.9% | 63.6% |
| Renters B25003 | 58.6% | 43.1% | 36.4% |
| Median home value B25077 | $362,200 | $373,600 | $404,200 |
| Median gross rent B25064 | $1,408 | $1,312 | $1,342 |
| White, not Hispanic B03002 | 33.1% | 56.5% | 68.0% |
| Black B03002 | 10.2% | 7.0% | 4.9% |
| Hispanic or Latino B03002 | 45.3% | 25.6% | 17.7% |
| Asian B03002 | 6.2% | 4.2% | 3.5% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Providence, RI.
Comments